Abstract
Overactivity of platelet-derived growth factor (PDGF) has been linked to malignant cancers. High levels of PDGF result in the activation of its receptors (PDGFRs) and the over-proliferation of cells. Therefore, interfering with this signaling pathway in cancer cells could be significant for anti-cancer drug development. In a previous study, the sPDGFRα-Fc fusion protein expressed in static CHO-k1 cells showed an anti-proliferative effect on vascular endothelial cells. However, it was difficult to obtain a large quantity of this fusion protein for further functional studies. In the present study, the sPDGFRα-Fc fusion protein was transiently expressed in Chinese Hamster Ovary (CHO) DG44 cells in 50-mL orbital shaking bioreactors. sPDGFRα-Fc was expressed as a 250-kDa dimeric protein with potential glycosylation. The final yield of sPDGFRα-Fc in the culture supernatant was as high as 16.68 mg/L. Our results suggest that transient expression in orbital shaking bioreactors may be feasible for preparation of recombinant proteins used for preclinical studies.
Keywords: PDGF, soluble PDGFRα-Fc, transient gene expression, CHO DG44 cells, Orbitally shaking bioreactor, disposable bioreactor
Protein & Peptide Letters
Title: Transient Expression of Recombinant sPDGFRα-Fc in CHO DG44 Cells using 50-mL Orbitally Shaking Disposable Bioreactors
Volume: 17 Issue: 7
Author(s): Yun-Xia Sang, Xiao-Wei Zhang, Xiao-Jia Chen, Kui Xie, Chui-Wen Qian, An Hong, Qiu-Ling Xie and Sheng Xiong
Affiliation:
Keywords: PDGF, soluble PDGFRα-Fc, transient gene expression, CHO DG44 cells, Orbitally shaking bioreactor, disposable bioreactor
Abstract: Overactivity of platelet-derived growth factor (PDGF) has been linked to malignant cancers. High levels of PDGF result in the activation of its receptors (PDGFRs) and the over-proliferation of cells. Therefore, interfering with this signaling pathway in cancer cells could be significant for anti-cancer drug development. In a previous study, the sPDGFRα-Fc fusion protein expressed in static CHO-k1 cells showed an anti-proliferative effect on vascular endothelial cells. However, it was difficult to obtain a large quantity of this fusion protein for further functional studies. In the present study, the sPDGFRα-Fc fusion protein was transiently expressed in Chinese Hamster Ovary (CHO) DG44 cells in 50-mL orbital shaking bioreactors. sPDGFRα-Fc was expressed as a 250-kDa dimeric protein with potential glycosylation. The final yield of sPDGFRα-Fc in the culture supernatant was as high as 16.68 mg/L. Our results suggest that transient expression in orbital shaking bioreactors may be feasible for preparation of recombinant proteins used for preclinical studies.
Export Options
About this article
Cite this article as:
Sang Yun-Xia, Zhang Xiao-Wei, Chen Xiao-Jia, Xie Kui, Qian Chui-Wen, Hong An, Xie Qiu-Ling and Xiong Sheng, Transient Expression of Recombinant sPDGFRα-Fc in CHO DG44 Cells using 50-mL Orbitally Shaking Disposable Bioreactors, Protein & Peptide Letters 2010; 17 (7) . https://dx.doi.org/10.2174/092986610791306733
DOI https://dx.doi.org/10.2174/092986610791306733 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Gut Alterations in Septic Patients: A Biochemical Literature Review
Reviews on Recent Clinical Trials An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Engineered E. coli as Vehicles for Targeted Therapeutics
Current Gene Therapy IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
Current Medicinal Chemistry Cyclodextrins for Non-Viral Gene and siRNA Delivery
Pharmaceutical Nanotechnology Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry Management of Early Stage Cervical Cancer
Reviews on Recent Clinical Trials Planar Bioadhesive Microdevices: A New Technology for Oral Drug Delivery
Current Pharmaceutical Biotechnology Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening
Endocrine, Metabolic & Immune Disorders - Drug Targets Rational Drug Design Paradigms: The Odyssey for Designing Better Drugs
Combinatorial Chemistry & High Throughput Screening Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design